Burning Rock Biotech Limited
BNR
$4.60
-$0.10-2.13%
| 09/30/2024 | 03/31/2024 | 12/31/2023 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -12.60% | -9.17% | -9.17% | -8.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -12.60% | -9.17% | -9.17% | -8.60% |
| Cost of Revenue | -- | -9.10% | -9.91% | -9.91% | -13.12% |
| Gross Profit | -- | -14.21% | -8.81% | -8.81% | -6.43% |
| SG&A Expenses | -- | -32.43% | -30.73% | -30.73% | -29.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -27.09% | -25.85% | -25.85% | -25.02% |
| Operating Income | -- | 36.19% | 35.39% | 35.39% | 34.20% |
| Income Before Tax | -- | 37.26% | 36.41% | 36.41% | 35.16% |
| Income Tax Expenses | -- | -12.55% | 19.77% | 19.77% | 371.85% |
| Earnings from Continuing Operations | -- | 37.19% | 36.30% | 36.30% | 34.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 37.19% | 36.30% | 36.30% | 34.79% |
| EBIT | -- | 36.19% | 35.39% | 35.39% | 34.20% |
| EBITDA | -- | 43.10% | 42.51% | 42.51% | 41.59% |
| EPS Basic | -- | 36.52% | 35.30% | 35.30% | 33.48% |
| Normalized Basic EPS | -- | 36.59% | 35.41% | 35.41% | 33.85% |
| EPS Diluted | -- | 36.52% | 35.30% | 35.30% | 33.48% |
| Normalized Diluted EPS | -- | 36.59% | 35.41% | 35.41% | 33.85% |
| Average Basic Shares Outstanding | -- | -0.92% | -1.46% | -1.46% | -1.95% |
| Average Diluted Shares Outstanding | -- | -0.92% | -1.46% | -1.46% | -1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
